Share
For a US biotech with a proven track record at home, EU and UK expansion is often the next logical growth step. But while Europe offers access to multiple high-value markets and a sophisticated scientific ecosystem, it operates through distinct regulatory pathways, country-level realities, and operational obligations that can catch teams off guard when an FDA-ready strategy is assumed to apply directly.
The opportunity is real. The difference between a smooth market entry and a costly detour usually comes down to one thing: early strategic planning grounded in real European regulatory experience.
Europe is technically demanding, but that is not a barrier. It is an environment where disciplined planning creates an advantage. For late-stage US biotechs, a strong EU and UK roadmap can accelerate value inflection points, open partnering opportunities, and reduce rework by aligning expectations early.
Successful EU expansion is typically driven by three principles:
- Selecting the right pathway based on product characteristics and ambition
- Designing EU and UK plans that acknowledge regional differences
- Building an execution model that fits organisational size and maturity
When these elements are in place, EU expansion becomes what it should be: a structured path toward sustainable growth.
From EU expansion strategy to execution
Successful EU and UK expansion requires more than regulatory knowledge; it requires an integrated strategy that connects pathway selection, clinical planning, CMC readiness, and operational governance.
QbD Group supports US biotechs in planning and executing EU expansion strategies that are realistic, scalable, and aligned with European regulatory expectations. 👉 Get in touch to discuss how to build a robust EU and UK expansion roadmap
Get in touch to discuss how to build a robust EU and UK expansion roadmap.
%20Checklist.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.png)